Despite progress in the discovery and design of b-lactams, b-lactamases continue to pose the most significant threat to our antibiotic armamentarium. Among the serine b-lactamases, the most widespread and problematic are the class A extended-spectrum (ES) ?-lactamases, the AmpC (class C) cephalosporinases, and the ES AmpCs. These ?-lactamases are found in ceftazidime resistant Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. In this proposal we will continue our work with boronic acid transition state inhibitors (BATSIs) as molecular probes to target the ES SHV of K. pneumoniae and the AmpC of P. aeruginosa, PDC-3. Our central hypothesis is that a better understanding of the molecular details of catalysis and inhibition of ?-lactamase enzymes can lead to the design of more effective inhibitors. With this, we formulate the following specific aims: 1. Complete our studies of ES SHV ?-lactamases by testing novel BATSIs possessing unique R1 side chains. We will use information obtained from susceptibility tests, kinetics, and X-ray crystallography to inform the design of novel functionalities that improve inhibitor affinity and specificity. 2. Define the sequence requirements, molecular, and kinetic interactions that characterize the catalysis and inhibition of PDC-3 ?-lactamase;a) To understand the interactions of PDC-3 with cephalosporins, carbapenems, and BATSIs on a deeper level, we will test the role of Thr105Ala, Thr289, Asn343, Asn346 and Arg349 in PDC-3 using site- saturation and Ala replacement mutagenesis. b) To investigate the properties of PDC-3 that permit the evolution of the ES and carbapenemase profile, we will introduce specific deletion mutations into the R2-loop of this PDC (D 303 - 306);3. Determine the apo crystal structure of PDC-3 and the structure of PDC-3 complexed with BATSIs possessing ceftazidime (LP06) and cefotaxime R1 side chains. This work defines important structure-function relationships in class A and C ?-lactamases and brings us closer to understanding the evolution of the ES cephalosporinases in the clinic as well as discovering effective inhibitors for this challenging drug target. We chose these ?-lactamases as they are among the most important class A and class C enzymes in Gram-negative bacteria.

Public Health Relevance

This proposal is a continuation of our investigations that use boronic acid transition state inhibitors (BATSIs) to understand why Gram-negative bacteria become resistant to extended-spectrum cephalosporins and carbapenems. We chose the beta-lactamases of Klebsiella pneumoniae and Pseudomonas aeruginosa as our target enzymes;these are among the most problematic pathogens found in the hospital setting. We will engineer mutations in these beta-lactamases to understand their catalytic properties, study the interactions of new inhibitors with these enzymes, and determine their structures by X-ray crystallography.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI063517-10
Application #
8659336
Study Section
Special Emphasis Panel (ZRG1-IDM-S (04))
Program Officer
Korpela, Jukka K
Project Start
2005-02-15
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
10
Fiscal Year
2014
Total Cost
$311,850
Indirect Cost
$64,350
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Chen, Liang; Hu, Hongyan; Chavda, Kalyan D et al. (2014) Complete sequence of a KPC-producing IncN multidrug-resistant plasmid from an epidemic Escherichia coli sequence type 131 strain in China. Antimicrob Agents Chemother 58:2422-5
Perez, Federico; Adachi, Javier; Bonomo, Robert A (2014) Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis 59 Suppl 5:S335-9
Heidari Torkabadi, Hossein; Bethel, Christopher R; Papp-Wallace, Krisztina M et al. (2014) Following drug uptake and reactions inside Escherichia coli cells by Raman microspectroscopy. Biochemistry 53:4113-21
June, Cynthia M; Vaughan, Robert M; Ulberg, Lucas S et al. (2014) A fluorescent carbapenem for structure function studies of penicillin-binding proteins, ?-lactamases, and ?-lactam sensors. Anal Biochem 463:70-4
Che, Tao; Bethel, Christopher R; Pusztai-Carey, Marianne et al. (2014) The different inhibition mechanisms of OXA-1 and OXA-24 ?-lactamases are determined by the stability of active site carboxylated lysine. J Biol Chem 289:6152-64
Perez, Federico; Deshpande, Abhishek; Kundrapu, Sirisha et al. (2014) Pseudo-outbreak of Klebsiella oxytoca spontaneous bacterial peritonitis attributed to contamination of multidose vials of culture medium supplement. Infect Control Hosp Epidemiol 35:139-43
Papp-Wallace, Krisztina M; Winkler, Marisa L; Gatta, Julian A et al. (2014) Reclaiming the efficacy of ?-lactam-?-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother 58:4290-7
Drawz, Sarah M; Papp-Wallace, Krisztina M; Bonomo, Robert A (2014) New ?-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-46
Farrell, John J; Larson, Joshua A; Akeson, Jeffrey W et al. (2014) Ureaplasma parvum prosthetic joint infection detected by PCR. J Clin Microbiol 52:2248-50
de Sanctis, Jorgelina; Teixeira, Lucileia; van Duin, David et al. (2014) Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections. Int J Infect Dis 25:73-8

Showing the most recent 10 out of 118 publications